Aug 10, 2026 04:20PM
Aug 10, 2026 04:20PM
Jun 30, 2026 06:45AM
Jun 29, 2026 08:30AM
Jun 29, 2026 08:30AM
Jan 7, 2026 08:17AM
Jan 7, 2026 08:15AM Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
Jan 7, 2026 08:15AM
Dec 30, 2025 08:35AM
Dec 30, 2025 08:35AM
Oct 28, 2025 08:45AM
Oct 28, 2025 08:45AM
Oct 20, 2025 08:45AM
Oct 20, 2025 08:45AM Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
Oct 13, 2025 08:46AM
Oct 13, 2025 08:45AM
Sep 17, 2025 09:00AM
Sep 17, 2025 09:00AM
Sep 5, 2025 08:45AM
Sep 5, 2025 08:45AM
Aug 7, 2025 09:15AM Palisade Bio reports positive phase 1b results for ulcerative colitis drug
Aug 7, 2025 09:15AM
Sep 25, 2024 08:01AM
Sep 25, 2024 08:00AM
Aug 13, 2024 08:05AM
May 29, 2024 06:47AM
May 14, 2024 08:05AM
Mar 27, 2024 08:00AM Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
Feb 8, 2024 08:05AM
Nov 22, 2022 08:57AM
Nov 22, 2022 08:36AM
Nov 22, 2022 08:35AM
Nov 22, 2022 08:35AM
Nov 18, 2022 08:05AM
Nov 18, 2022 08:05AM Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
Nov 18, 2022 08:05AM
May 13, 2022 09:00AM
May 5, 2022 08:31AM
May 5, 2022 08:30AM
May 2, 2022 08:35AM
Apr 29, 2022 08:05AM
Mar 22, 2022 08:31AM Palisade Bio Inc. (PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148
Mar 22, 2022 08:30AM
Mar 18, 2022 08:30AM
Mar 16, 2022 08:04AM
Mar 16, 2022 08:00AM
Dec 8, 2021 08:01AM
Dec 8, 2021 08:00AM
Aug 24, 2021 08:15AM Palisade Bio Reports Second Quarter Financial Results and Provides Business Update
Aug 20, 2021 09:28AM

329,909 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All